Teriflunomide (Aubagio™*) significantly reduces relapses

Aubagio is an oral treatment approved for MS.

Teriflunomide (Aubagio™*) significantly reduces relapses

Postby MSUK » Thu Oct 20, 2011 12:58 am


Sanofi and its subsidiary Genzyme announced today new data from the pivotal TEriflunomide Multiple Sclerosis Oral (TEMSO) Phase III trial showing that once-daily oral teriflunomide significantly reduced annualized rates of relapses leading to hospitalization. New data also confirmed the safety profile and efficacy of teriflunomide over a six-year period after the initial randomization.

A total of fifteen presentations on teriflunomide are on the program for the fifth joint triennial congress of the European and American Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS / ACTRIMS) in Amsterdam, Netherlands.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Aubagio (teriflunomide)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service